Gibson Dunn & Crutcher advised Merck on the transaction and Wilson Sonsini Goodrich & Rosati advised LaNova Medicines. Merck (NYSE: MRK), known as MSD outside of...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini advised Circle Pharma on the transaction. Circle Pharma (Circle), a clinical-stage biopharmaceutical company dedicated to discovering and developing cell-permeable macrocycles as a new class...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Dren Bio on the transaction. Dren Bio, Inc., a privately held, clinical-stage biopharmaceutical company developing antibody therapeutics for cancer, autoimmune,...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Absci on the transaction. Absci Corporation (Nasdaq: ABSI) announced a collaboration with AstraZeneca, a global biopharmaceutical company, to deliver an AI-designed...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati and Latham & Watkins advised CARGO Therapeutics, Inc. on the offering, and Cooley advised the underwriters. CARGO Therapeutics, Inc. (CARGO) (Nasdaq:CRGX)...
You must be a Standard 1 Year member to access this content.
Sidley Austin LLP advised Pyxis Oncology, Inc. on the transaction, while Wilson Sonsini advised Apexigen on the transaction. Pyxis Oncology, Inc., a clinical-stage company, and Apexigen,...
You must be a Standard 1 Year member to access this content.
Orrick advised Third Rock Ventures on the deal while Wilson Sonsini represented CARGO Therapeutics. Third Rock Ventures announced its investment in the $200 million Series A financing...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Insilico Medicine on the transaction. Insilico Medicine, a clinical-stage artificial intelligence-driven drug discovery company, announced a multi-year, multi-target strategic research...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini advised Kedalion Therapeutics on the deal. Novartis announced that it acquired Kedalion Therapeutics and its AcuStream technology, an innovative device that may have the...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Chroma Medicine on the deal. Chroma Medicine, a new genomic medicine company pioneering epigenetic editing, launched with $125 million in...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati and Taylor Wessing advised WuXi AppTec on the deal. WuXi AppTec, a leading global provider of R&D- and manufacturing-enabling services in...
You must be a Standard 1 Year member to access this content.
